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Abstract
Background The human Y-box-binding protein 1 (YB-1)
is a member of the DNA/RNA-binding family of proteins
that regulates transcription and translation of genes. Pre-
vious studies suggest that YB-1 may have an oncogenic
role in various cancers. In this study, we evaluate the
prognostic value of cytoplasmic YB-1 with respect to
breast cancer.
Methods Immunohistochemical staining study was per-
formed with YB-1 using tissue block from 233 patients
with invasive ductal carcinoma. Patients were divided into
two groups according to expression of cytoplasmic YB-1 in
tumor cell (high versus low). The relationship between the
expression of YB-1, clinicopathological characteristics and
breast cancer prognosis was analyzed.
Results Hormone receptor negativity, worse histologic
and nuclear grade, high tumor stage, lymphovascular
invasion and high Ki67 (C14 %) were related with the
increased expression of cytoplasmic YB-1 in tumor cell
(p\ 0.05). Although there was no significant difference in
relapse-free survival (RFS) between the two groups
(p = 0.412), difference in overall survival (OS) was sta-
tistically significant (p = 0.035). In multivariate analysis
for OS, YB-1 was an independent prognostic factor
(p = 0.043).
Conclusion This suggests that the increased expression of
cytoplasmic YB-1 in tumor cells can be regarded as an
independent prognostic factor for breast cancer, related to
poor prognostics. Expression of cytoplasmic YB-1 in
cancer cell could be used as an independent prognostic
marker for predicting OS in breast cancer.
Keywords YBX1 protein  Human  Cytoplasm 
Prognosis  Breast neoplasm
Introduction
Breast cancer is the most common cancer for women and
its incidence is gradually increasing [1]. It is a kind of
heterogeneous disease due to its broad spectrum of mor-
phological features, clinical manifestations, and treatment
responses [2]. Therefore, it needs various makers for pre-
dicting prognosis and many previous studies have searched
for new markers for prognosis and treatment in breast
cancer.
Recently, the human Y-box-binding protein 1 (YB-1)
has been suggested as a new prognostic marker in many
studies. YB-1 is a nucleic acid binding protein, which is
located in chromosome 1p34. The process that cold shock
domain of YB-1 binds with the Y-box in the gene promoter
regulates gene transcription and translation. YB-1 is also
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known to be involved in DNA repair, splicing, stabiliza-
tion, cell proliferation and regeneration [3–5].
Several studies have reported on the oncogenic role of
YB-1 and mainly focused on the nuclear expression of
YB-1 in tumor cell. Nuclear expression of YB-1 in tumor
cells is known to be associated with poor prognosis in
various types of cancer [6–9]. It has been also reported to
be involved in multidrug resistance. Translocation of YB-
1 into nucleus activates the transcription of multidrug
resistance (MDR) 1 gene and the expression of P-glyco-
protein, subsequently producing drug resistance [10]. In
matter of breast cancer, YB-1 has been reported to induce
human epidermal growth factor receptor (HER)-2. The
nuclear expression of YB-1 has been introduced to be
related with the negative expression of estrogen receptor
(ER) and progesterone receptor (PR) [11]. Furthermore,
according to previous report, it has been also known that
cytoplasmic expression of YB-1 is related with cancer
prognosis [12].
Based on these considerations, this study aims to eval-
uate the significance of cytoplasmic YB-1 expression for
prognosis prediction in breast cancer.
Methods
Patient selection
Between January 2003 and December 2008, a total of 538
patients underwent breast cancer surgery at the Department
of Surgery, Ewha Womans University Mokdong Hospital.
Among these patients, 233 patients were finally enrolled in
this study. Patient exclusion criteria were as follows: (1)
male, (2) patient who received neoadjuvant chemotherapy,
(3) ductal carcinoma in situ, (4) distant metastasis at the
time of diagnosis, (5) 2? for HER2 by immunohisto-
chemistry (IHC), (6) death unrelated with breast cancer, (7)
patient with other concomitant cancer (except papillary
thyroid cancer, cervical intraepithelial neoplasia:CIN, non-
melanoma skin cancer) and (8) patient with no paraffin
block or inappropriate paraffin block for study. Molecular
subtype was defined as follows: luminal A (ER? and/or
PR?, Ki67\ 20 and HER2-), luminal B (ER? and/or
PR?, Ki67 C 20 and/or HER2?), HER2? enrich (ER-,
PR- and HER2?) and triple negative breast cancer
(TNBC) (ER-, PR- and HER2-). Cases with 2? score
were excluded from this study because fluorescent in situ
hybridization (FISH) was not performed at our institute
prior to 2006.
This study was approved by the Institutional Review
Board of Ewha Womans University Mokdong Hospital
(IRB approval number, 12-16A-18).
Immunohistochemical staining
Formalin-fixed paraffin sections (2.5 lm) of tumor tissues
were deparaffinized with xylene and rehydrated in graded
alcohols. Immunohistochemical staining was done with the
Dako Envision system, which uses dextran polymers con-
jugated with horseradish peroxidase (Dako, Carpinteria,
CA, USA). For antigen retrieval, the slides in a target
retrieval solution (pH 6.0; DAKO) were boiled for 10 min
in a microwave oven. Tissue sections were incubated in a
humidified box at 4 C overnight with a primary antibody
(Ab) against YB-1 (1:100 dilutions, Novus USA). After
incubation, the sections were treated with an Envi-
sion?System-HRP secondary Ab (DaKo). Color develop-
ment was conducted using 3-amino-9-ethylcarbazole
(AEC) (DAKO) as a chromogen. Finally, all sections were
counterstained with hematoxylin (DaKo). Negative control
sections were treated in the same manner except if they
were incubated with Tris-buffered saline without primary
Ab.
Interpretation
To evaluate the expression for YB-1, two pathologists
independently reviewed the slides using an immunoreac-
tivity score (IRS) without any patient information. IRS was
evaluated by multiplying the intensity score by percentage
of positive tumor cells. The staining results were scored by
(1) intensity scores: 0 (no staining), 1 (weak), 2 (moderate),
3(strong); and (2) percentage of positive tumor cells: 0
(0–10 %), 1 (11–25 %), 2 (26–50 %), 3 (51–75 %), 4
(76–100 %). Patients were divided into two groups
according to IRS. Scores 0–4 were considered as the low
expression group (low group) and 5–12 were considered as
the high expression group (high group) (Fig. 1). We
determined score which showed best statistical results for
prognostic factors and prognosis as cutoff value. Expres-
sions of Hormone receptor and HER2? were determined
based on IHC profiles. ER/PR positivity was defined when
more than 10 % of cancer cells were stained with more
than 1? of intensity. In respect to c-erbB2 expression,
score of 3? was regarded as positive and scores of 0, 1?
were regarded as negative.
Statistical analysis
Pearson’s Chi-square test and Fisher’s exact test were used
to compare patient’s clinicopathologic characteristics.
Relapse-free survival (RFS) was defined as a length of time
from surgery to relapse of cancer and overall survival (OS)
was defined as from surgery to breast cancer related death
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and analyzed by the Kaplan–Meier method. Univariate
analysis was performed using Log-rank test and multi-
variate analysis was performed using Cox’s proportional
hazard model with 95 % confidence interval (CI). The
mean value comparison of chemotherapeutic agents was
conducted by the Mann–Whitney test. All statistical tests
were performed by SPSS (version 18, SPSS Inc., Chicago,
IL, USA) and p value\0.05 was considered as statistically
significant in all results.
Results
Clinicopathologic characteristics of all patients
A total of 233 females were included in this study and
their mean age was 50.2 ± 11.0 years. Median follow-up
duration was 59.0 ± 25.1 months. Among the 233
patients, 14 patients (6.0 %) were younger than 35 years
old. 106 patients (45.5 %) received breast conserving sur-
gery (BCS) and 127 patients (54.5 %) underwent
mastectomy.
In terms of histologic types, there were 227 cases
(97.4 %) of invasive ductal carcinoma and 6 cases (2.6 %)
of invasive lobular carcinoma (ILC). Table 1 shows the
clinicopathologic characteristics of all patients.
Expression of YB-1 in breast cancer cell
and relationship between expression of cytoplasmic
YB-1 and prognostic factors
Cytoplasmic YB-1 expression in cancer cell was evaluated
using IRS. High expressions of YB-1 (score 5–12) were
observed in 112 (48.1 %) patients and low expressions
(score 0–4) were observed in 121 patients (Fig. 1).
Table 2 presents the relationship between expression of
cytoplasmic YB-1 and prognostic factors. High expression
of cytoplasmic YB-1 was more frequently observed in ER,
PR negative tumor than in positive tumor (p\ 0.001).
Regarding to molecular subtypes, there were more HER2
type tumor and TNBC in the high expression group
(p\ 0.001). High expression of cytoplasmic YB-1 was
related with histologic and nuclear grade III tumors
(p\ 0.001). Tumors with high ki-67 were more frequently
Fig. 1 Four different patterns of microscopic findings of immuno-
histochemical staining for YB-1 expression in showing this study.
a YB-1 was not expressed in cytoplasm and nucleus. b YB-1 was
expressed weakly in cytoplasm. c YB-1 was expressed strongly in
cytoplasm but not in the nucleus. d YB-1 was expressed strongly in
both cytoplasm and nucleus (black arrows and circles)
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observed in high expression group (p\ 0.001). Tumor
stage was also significantly related with high cytoplasmic
YB-1 expression (p = 0.017).
Table 1 Clinicopathologic characteristics in this study
Patient characteristics Number of patients (%)
Age
\35 14 (6.0 %)
C35 219 (94.0 %)
Operation
BCS 106 (45.5 %)
MRM 127 (54.5 %)
Histology
IDC 227 (94.4 %)
ILC 6 (5.6 %)
ER
Negative 73 (31.3 %)
Positive 160 (68.7 %)
PR
Negative 85 (36.5 %)
Positive 148 (63.5 %)
c-erbB2
Negative 156 (67.0 %)
Positive 77 (33.3 %)
Histologic grade
1 72 (30.9 %)
2 101 (43.3 %)
3 55 (23.6 %)
Unknown 5 (2.2 %)
Nuclear grade
1 39 (16.7 %)
2 130 (55.8 %)
3 59 (25.3 %)
Unknown 5 (2.2 %)
Ki67
\20 136 (58.4 %)
C20 97 (41.6 %)
T stage
1 116 (49.8 %)
2 103 (44.2 %)
3 13 (5.6 %)
4 1 (0.4 %)
N stage
0 145 (62.8 %)
1 55 (23.8 %)
2 18 (7.8 %)
3 13(5.6 %)
BCS breast conserving surgery, MRM modified radical mastectomy,
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER
estrogen receptor, PR progesterone receptor
Table 2 Comparisons of clinicopathologic results according to
expression of YB-1
Patient characteristics Number of patients (%) p value
Low (n = 121) High (n = 112)
Age 0.210
\35 5 (4.1 %) 9 (8.0 %)
C35 116 (95.9 %) 103 (92.0 %)
Operation 0.117
BCS 61 (50.4 %) 45 (40.2 %)
MRM 60 (49.6 %) 67 (59.8 %)
Histology 0.119
IDC 116 (95.9 %) 111 (99.1 %)
ILC 5 (4.1 %) 1 (0.9 %)
ER \0.001
Negative 18 (14.9 % 55 (49.1 %)
Positive 103 (85.1 %) 57 (50.9 %)
PR \0.001
Negative 28 (23.1 %) 57 (50.9 %)
Positive 93 (76.9 %) 55 (49.1 %)
c-erbB2 0.051
Negative 88 (72.7 %) 68 (60.7 %)
Positive 33 (27.3 %) 44 (39.3 %)
Molecular subtype \0.001
Luminal A 64 (52.9 %) 30 (26.8 %)
Luminal B 41 (33.9 %) 32 (28.6 %)
HER2 enrich 9 (7.4 %) 25 (22.3 %)
TNBC 7 (5.8 %) 25 (22.3 %)
Histologic grade \0.001
1 52 (44.4 %) 20 (18.0 %)
2 52 (44.4 %) 49 (44.1 %)
3 13 (11.1 %) 42 (37.8 %)
Unknown 4 1
Nuclear grade \0.001
1 30 (25.6 %) 9 (8.1 %)
2 72 (61.5 %) 58 (52.3 %)
3 15 (12.8 %) 44 (39.6 %)
Unknown 4 1
Ki67 \0.001
\20 86 (71.1 %) 50 (44.6 %)
C20 35 (28.9 %) 62 (55.4 %)
T stage 0.017
1 70 (57.9 %) 46 (41.1 %)
2 47 (38.8 %) 56 (50.0 %)
3 3 (2.5 %) 10 (8.9 %)
4 1 (0.8 %) 0
N stage 0.070
0 78 (64.5 %) 68 (60.7 %)
1 33 (27.3 %) 22 (19.6 %)
2 6 (5.0 %) 13 (11.6 %)
3 4 (3.3 %) 9 (8.0 %)
BCS breast conserving surgery, MRM modified radical mastectomy,
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER
estrogen receptor, PR progesterone receptor, TNBC triple negative
breast cancer
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Prognosis according to cytoplasmic YB-1 expression
Kaplan–Meier analysis was conducted to evaluate RFS and
OS according to expression of cytoplasmic YB-1. In RFS,
there was no significant difference between the two groups
(p = 0.412) (Fig. 2a). In terms of OS, 5-year survival rates
of the high and low group were 92 and 98 %, respectively,
showing a significant difference between the two groups
(p = 0.035) (Fig. 2b). Multivariate analysis was performed
using Cox proportionate hazard regression model and high
expression of cytoplasmic YB-1 was confirmed as an
independent prognostic factor for OS (p = 0.043)
(Table 3).
Discussion
YB-1 is a DNA- and RNA-binding protein, which is
located on chromosome 1p34 and involved in various
cellular processes. This protein plays a role in DNA
replication, repair, transcription, pre-mRNA splicing, and
mRNA translation [3–5]. It was reported that the expres-
sion of YB-1 increases in cancer cells and its high
expression or expression in nucleus were associated with
poor prognosis in many types of cancer [6–9, 13]. Also,
this nuclear expression of YB-1 in tumor cell activates
gene transcription for protein and relates to multidrug
resistance and ionizing radiation [10, 14].
In breast cancer, the oncogenic role of YB-1 has been
widely studied. Previous studies showed that the localiza-
tion of YB-1 in nucleus was associated with poor prognosis
as well as with poor prognostic factors [8, 11, 15]. Some
studies showed that the nuclear YB-1 expression was
positively correlated with the HER2 expression and sug-
gested the inhibition of YB-1 could be a good therapeutic
target for HER2 type tumor [15–17]. Ito et al. [18] found
that the alteration of YB-1 after neoadjuvant chemotherapy
might modify the crosstalk between ER and HER2 path-
ways, leading to endocrine therapy resistance. According
to the study of Li et al. [12], high expression of YB-1 in
cytoplasm of cancer cell was significantly associated with
poor prognosis in squamous esophageal cancer. However,
their study did not show a significant relationship between
YB-1 expression and prognostic factors.
In this study, we could observe high cytoplasmic
expressions of YB-1 in 112 (48.1 %) patients and YB-1
was also expressed in cancer cell nucleus. Nuclear
expression of YB-1 was also significantly related with poor
prognostic factors (ER and PR negativity, high histologic
and nuclear grade, high Ki-67 expression) and poor OS
(data were not shown). However, such an expression was
observed in 26 out of 233 cases (11.2 %) and this was a
relatively small proportion compared to previous studies
[8, 11, 15]. Some previous studies reported that nuclear
localization of YB-1 was induced by growth factors and
cytokines and related with tumor progression [19–21]. This
means that more advanced and aggressive cancer expresses
more amounts of nuclear YB-1. In our study, tumors were
relatively in their early stages compared to those of pre-
vious studies. We consider this finding may have con-
tributed to the lower nuclear expression of YB-1. Actually,
among the 26 patients with nuclear expression of YB-1,
Fig. 2 Relapse-free survival and overall survival analysis according to YB-1 expression. a Relapse-free survival according to YB-1 expression,
b overall survival analysis according to YB-1 expression
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both nucleus and cytoplasm of YB-1 were observed in 24
patients (99.1 %) and these tumors showed relatively high
T stage, high histologic and nuclear grade, more aggressive
biologic features compared to the tumors expressed YB-1
only in cytoplasm.
Our study showed that high IRS group was significantly
related with ER/PR positive, high Ki-67, high histologic
grade, high nuclear grade and high T stage (p\ 0.05).
Although, c-erbB2 was not significantly related with the
high expression of YB-1, there was a tendency that tumor
with positive c-erbB2 expressed high YB-1 (p = 0.051).
The High group was also associated with poor OS
(p = 0.035), but not with RFS (p = 0.412). Subsequently,
recurrence patterns according to YB-1 expression were
analyzed based on a total of 23 tumor recurrences that were
observed. Among them, 13 recurrence cases were observed
in the high group and the other 10 recurrence cases in the
low group. There were a total of 17 systemic recurrences
where 12 (70.6 %) were observed in the high group and 5
(29.4 %) in the low group (p = 0.022). These recurrence
patterns might be contributing towards the significant dif-
ference in OS between the two groups (Table 4). Accord-
ing to previous studies, elevated expression of YB-1 in
cancer cell promotes epithelial-mesenchymal transition in
various cancers including breast cancer, and this is also
related with angiogenesis in tumor microenvironment [22–
24]. We think that this mechanism might affect more fre-
quent systemic recurrence and poor OS in the high group.
Additionally, during the molecular subgroup analysis for
recurrence cases in the high group, three (23.1 %) cases
were TNBC, two (15.4 %) were HER2? type tumors and
the rest were luminal type (A or B) tumors. In the low
group, there was no TNBC while there was one (10.0 %)
and nine cases (90.0 %) of HER2? type and luminal (A or
B) types, respectively. Yi et al. [25] reported that TNBC
patients had shorter OS than non-TNBC patients despite
favorable response to palliative doxorubicin based
chemotherapy. They assumed that this might be due to
frequent resistance to chemotherapeutic agent in TNBC.
Our prognostic results might be also affected by this
mechanism.
There were some limitations of this study. Because our
cases were composed of relatively early stage tumors
compared to previous studies, there may be fewer cancer
related deaths and recurrences compared to other studies
[8, 11, 15]. Therefore, this study could not show the
independent role of established prognostic factors except
the nodal stage.
Conclusion
This study showed cytoplasmic expression of YB-1 was
associated with more aggressive tumor and poor overall
survival in breast cancer. Therefore, high cytoplasmic
expression of YB-1 in cancer cell could be used as an
independent prognostic marker for predicting OS in breast
cancer. Furthermore, developing a new targeting agent for
YB-1 in cancer cell could be a novel progress in breast
cancer treatment.
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